Fubotv earnings beat by $0.10, revenue topped estimates
Mangoceuticals , Inc. (NASDAQ:MGRX), a Texas-based health services company, announced on Monday that it has entered into a consulting agreement with 6330 Investment & Consulting Gmbh. The consultancy firm is tasked with identifying strategic partners and potential acquisition opportunities for the company.
According to the agreement signed on Monday, 6330 Consulting will provide these advisory services for a 12-month period, with the possibility of earlier termination in case of a breach that remains uncured after 30 days of written notice. As compensation for their services, Mangoceuticals has agreed to issue 200,000 shares of its restricted common stock to 6330 Consulting.
In a separate matter, on February 14, 2025, Mangoceuticals fulfilled a warrant exercise by issuing 80,000 shares of common stock at $1.50 per share, receiving an aggregate exercise price of $120,000. The issuance of shares to both the warrant holder and 6330 Consulting are claimed to be exempt from registration under the Securities Act of 1933, citing Section 4(a)(2) as the transactions did not involve a public offering. The shares issued are restricted, bearing the standard legend stating they have not been registered under the Securities Act and are subject to restrictions on transfer. For deeper insights into MGRX’s financial health and 12 additional exclusive ProTips, visit InvestingPro.
Mangoceuticals has made the details of the consulting agreement available in an exhibit filed with the SEC. This move by the company is part of its broader strategy to expand its business through strategic partnerships and acquisitions, particularly important given that InvestingPro data shows its short-term obligations currently exceed liquid assets. The information provided in this article is based on the company’s recent SEC filing.
In other recent news, Mangoceuticals, Inc. has been actively advancing its research on respiratory illness prevention, specifically targeting the H1N1 and H5N1 viruses. The company, in collaboration with Vipragen Biosciences and Intramont Technologies, is conducting studies that have shown promising preliminary results in reducing viral loads. Additionally, Mangoceuticals has made changes to its corporate structure by introducing a new class of Series A Super Majority Voting Preferred Stock, granting significant voting rights to holders, which could affect corporate decision-making. The company has also entered into a new service agreement with Greentree Financial Group to assist with compliance filings and tax returns, in exchange for equity and cash payments. Furthermore, Mangoceuticals is investigating potential stock manipulation following a reverse stock split, which led to an unusual increase in shareholder accounts. Lastly, the company has issued shares to Platinum Point Capital, part of an Equity Purchase Agreement, potentially raising up to $25 million over two years. These developments highlight Mangoceuticals’ ongoing efforts to expand its research, restructure its governance, and manage its financial operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.